Reuters was two-and-a-half minutes ahead of rivals on Eli Lilly’s unscheduled trading update, which showed fourth-quarter sales of its weight-loss drug Zepbound would miss Wall Street estimates. The drugmaker’s shares slumped 8% on the news.